GB202214232D0 - Clostridial neurotoxins comprising an activating exogenous protease cleavage site - Google Patents

Clostridial neurotoxins comprising an activating exogenous protease cleavage site

Info

Publication number
GB202214232D0
GB202214232D0 GBGB2214232.7A GB202214232A GB202214232D0 GB 202214232 D0 GB202214232 D0 GB 202214232D0 GB 202214232 A GB202214232 A GB 202214232A GB 202214232 D0 GB202214232 D0 GB 202214232D0
Authority
GB
United Kingdom
Prior art keywords
cleavage site
protease cleavage
exogenous protease
clostridial neurotoxins
activating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2214232.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ispen Biopharm Ltd
Original Assignee
Ispen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ispen Biopharm Ltd filed Critical Ispen Biopharm Ltd
Priority to GBGB2214232.7A priority Critical patent/GB202214232D0/en
Publication of GB202214232D0 publication Critical patent/GB202214232D0/en
Priority to PCT/GB2023/052512 priority patent/WO2024069176A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24068—Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GBGB2214232.7A 2022-09-28 2022-09-28 Clostridial neurotoxins comprising an activating exogenous protease cleavage site Pending GB202214232D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2214232.7A GB202214232D0 (en) 2022-09-28 2022-09-28 Clostridial neurotoxins comprising an activating exogenous protease cleavage site
PCT/GB2023/052512 WO2024069176A1 (en) 2022-09-28 2023-09-28 Clostridial neurotoxins comprising an activating exogenous protease cleavage site

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2214232.7A GB202214232D0 (en) 2022-09-28 2022-09-28 Clostridial neurotoxins comprising an activating exogenous protease cleavage site

Publications (1)

Publication Number Publication Date
GB202214232D0 true GB202214232D0 (en) 2022-11-09

Family

ID=83978661

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2214232.7A Pending GB202214232D0 (en) 2022-09-28 2022-09-28 Clostridial neurotoxins comprising an activating exogenous protease cleavage site

Country Status (2)

Country Link
GB (1) GB202214232D0 (en)
WO (1) WO2024069176A1 (en)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
AU3658093A (en) 1992-02-10 1993-09-03 Seragen, Inc. Desensitization to specific allergens
GB9305735D0 (en) 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
WO1999058571A2 (en) 1998-05-13 1999-11-18 BioteCon Gesellschaft für Biotechnologische Entwicklung und Consulting mbH Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof
DK1098664T3 (en) 1998-07-22 2003-11-17 Osprey Pharmaceuticals Ltd Compositions and Their Uses to Treat Secondary Tissue Damage and Other Inflammatory Conditions and Disorders
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
CA2380457A1 (en) 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
DE102004043009A1 (en) 2004-09-06 2006-03-23 Toxogen Gmbh Transport protein for introducing chemical compounds into nerve cells
CA2595115C (en) 2004-12-01 2014-01-21 Health Protection Agency Fusion proteins for treating, preventing or ameliorating pain
DE102005019302A1 (en) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier for targeting nerve cells
DK2154151T3 (en) 2005-09-19 2011-09-05 Allergan Inc Clostridium toxin inactivated clostridium toxins
EP1834962A1 (en) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGylated mtutated Clostridium botulinum toxin
EP2038299A2 (en) 2006-07-11 2009-03-25 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
EP2038298A2 (en) 2006-07-11 2009-03-25 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
GB0903006D0 (en) 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
WO2010120766A1 (en) 2009-04-14 2010-10-21 Mcw Research Foundation, Inc. Engineered botulinum neurotoxin
US8853360B2 (en) 2010-06-23 2014-10-07 Wisconsin Alumni Research Foundation Engineered botulinum neurotoxin C1 with selective substrate specificity
DK3372239T3 (en) 2012-05-30 2021-02-01 Harvard College MANIPULATED BOTULINUM NEUROTOXIN
EP3981783A1 (en) 2015-03-26 2022-04-13 President And Fellows Of Harvard College Engineered botulinum neurotoxin
DK3481852T3 (en) 2016-07-08 2023-02-27 Childrens Medical Center UNKNOWN BOTULINUM NEUROTOXIN AND ITS DERIVATIVES
BR112020006827A2 (en) 2018-01-29 2020-10-06 Ipsen Biopharm Limited botulinum neurotoxins cleaving non-neuronal snare
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
KR20220154738A (en) 2020-03-16 2022-11-22 입센 바이오팜 리미티드 Modified botulinum neurotoxin for treating limb spasticity
GB202003813D0 (en) 2020-03-16 2020-04-29 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202103372D0 (en) * 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
WO2023041934A1 (en) 2021-09-16 2023-03-23 Ipsen Biopharm Limited Modified bont/a for use in the treatment of cervical dystonia
WO2023047127A1 (en) 2021-09-23 2023-03-30 Ipsen Biopharm Limited Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject
WO2023089343A1 (en) 2021-11-22 2023-05-25 Ipsen Biopharm Limited Treatment of pain

Also Published As

Publication number Publication date
WO2024069176A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
MX2020007596A (en) Non-neuronal snare-cleaving botulinum neurotoxins.
WO2019040935A8 (en) Evolution of bont peptidases
MX2020010262A (en) Manufacture of recombinant clostridium botulinum neurotoxins.
WO2008021987A3 (en) Proteolytic enzyme formulations
AU2016204285A1 (en) Methods of intracellular conversion of single-chain proteins into their di-chain form
CO2019014682A2 (en) Compositions and methods for internalizing enzymes
IL281814A (en) Clostridial neurotoxins comprising an exogenous activation loop
NZ601094A (en) Modified cry1ca insecticidal cry proteins
MX2021006714A (en) Cationic neurotoxins.
WO2004076634A3 (en) Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
GB202214232D0 (en) Clostridial neurotoxins comprising an activating exogenous protease cleavage site
AR118443A1 (en) FUSION PROTEINS, RECOMBINANT BACTERIA AND EXOSPORAL FRAGMENTS FOR PLANT HEALTH AND PEST CONTROL
IN2015DN01570A (en)
WO2013037889A3 (en) Vaccine
EP3981428A4 (en) Protease substrate, and polypeptide including protease cleavage sequence
PH12020500420A1 (en) Apparatus and method for spraying color into cracks of a moving formed quartz slab to create veins in engineered stone
GB202214229D0 (en) Clostridial neurotoxins comprising an activating endosomal protease cleavage site
GB202103372D0 (en) Modified clostridial neurotoxins
MX2022005676A (en) Barcoded xten polypeptides and compositions thereof, and methods for making and using the same.
EP3930714A4 (en) Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents
WO2009024142A3 (en) Protease-stable, cell wall-lysing enzymes
GB202104294D0 (en) Clostridial neurotoxins comprising an exogenous activation loop
MX348766B (en) Expression method.
EP4116416A4 (en) Novel serine protease variant
EP4053272A4 (en) Novel serine protease variant